# A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

> **NCT07506109** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 49 (estimated)

## Conditions studied

- BRAF V600E
- Colorectal Cancer
- Sintilimab
- MSS (Microsatellite Stable)
- Cetuximab
- Dabrafenib
- Ipilimumab N01

## Interventions

- **DRUG:** Ipilimumab N01
- **DRUG:** Sintilimab
- **DRUG:** Cetuximab
- **DRUG:** Dabrafenib

## Key facts

- **NCT ID:** NCT07506109
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07506109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07506109, "A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07506109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*